PC3

Work Anywhere, Do Everything with Dell

Retrieved on: 
Thursday, March 23, 2023
Cloud, Small business, Aluminium, CrowdStrike, QHD, BIOS, VDI, Privacy, Mathematical optimization, Ada, PC3, Dell OptiPlex, Software, Freedom, Mobile device management, Phonation, Transverse mode, Human, Precision, Joseph Mydell, Philosophy, Intel, Lenovo, Dell Vostro, Alienware, PCR, Plastic, XPS, Dell, Multimedia, Carbon, DDR5, Thought, Rest, IPS, Gen4 Energy, Intelligence, Security, NVIDIA, Linux, AI, Ecosystem, Copper, I9, Dell Inspiron, Television, Satellite navigation device, Video game, Cassette tape, Online shopping, Recycling, Cryptocurrency, Payment card, Dell monitors

ROUND ROCK, Texas, March 23, 2023 /PRNewswire/ -- Let's face it, how we work and where we work today is different for everyone. Whether it's hybrid work, remote work, flexible work or in-office work, one thing is fundamentally consistent: technology. It is the great equalizer driving collaboration and productivity, providing new experiences of flexibility and freedom.

Key Points: 
  • ROUND ROCK, Texas, March 23, 2023 /PRNewswire/ -- Let's face it, how we work and where we work today is different for everyone.
  • Whether it's hybrid work, remote work, flexible work or in-office work, one thing is fundamentally consistent: technology.
  • While today many can work from anywhere, there are still limitations hindering our work experiences.
  • 11 This is based on a Dell internal study, testing power and performance within our Dell Optimizer power module.

Fibocom Launches FWA-dedicated 5G Module FG370 at Broadband World Forum 2022

Retrieved on: 
Tuesday, October 18, 2022
Cortex, Tao, 3GPP, NSA, MLO, QAM, Communication, General manager, FWA, LTE-FDD, Carrier aggregation, Android, WCDMA, Multimedia, Arm, RJ11, HPUE, IEEE 802.11be, LTE, CPE, Internet, SLIC, LTE-TDD, PC2, PC3, Solution, MiFi, MediaTek, Mobile phone, IOT

SHENZHEN, China, Oct. 18, 2022 /PRNewswire/ -- Fibocom (Stock code: 300638), a global leading provider of IoT (Internet of Things) wireless solutions and wireless communication modules, announced the global launch of 5G module FG370 at Broadband World Forum 2022. Powered by the newly-launched MediaTek T830 platform, FG370 is set to bring enhanced mobile broadband, low latency, and ultra-reliable 5G Fixed Wireless Access (FWA) connectivity solution for global operators.

Key Points: 
  • At Broadband World Forum 2022, Fibocom launched 5G module FG370 based on MediaTek T830 platform, aiming to empower the deployment of 5G FWA for carriers and customers worldwide.
  • SHENZHEN, China, Oct. 18, 2022 /PRNewswire/ -- Fibocom (Stock code: 300638), a global leading provider of IoT (Internet of Things) wireless solutions and wireless communication modules, announced the global launch of 5G module FG370 at Broadband World Forum 2022.
  • Compliant with 3GPP Release 16 (R16) standards, the 5G Sub-6GHz module FG370 enables lightning-fast 5G speed experience with up to 7.01Gbps on the downlink and 2.5Gbps on the uplink theoretically.
  • The module also integrates MediaTek's 5G UltraSave technologies to optimize energy efficiency for 5G connections, especially 5G MiFi.

Qualigen Therapeutics Presents Three Posters of QN-302 at American Association of Cancer Research Conference

Retrieved on: 
Tuesday, April 12, 2022
Protein, Patent, News, Medicine, Clinical trial, Poster, U.S. Securities and Exchange Commission, Mouse, Adult, Security (finance), Acetic anhydride, Risk, Cancer, Private Securities Litigation Reform Act, Patient, G4S, PDAC, Form 10-K, Conference, Survivor, Company, RAS, AML, Neoplasm, Prostate cancer, 2021 Essex County Council election, Fast Track, Immortalised cell line, PDX, FDA, Treatment of lung cancer, Orphan drug, PC3, AACR, Acute myeloid leukemia, Medical imaging, Pharmaceutical industry

Pancreatic cancer remains a high unmet medical need with limited treatment options. According to the American Cancer Society, about 62,210 will be diagnosed with pancreatic cancer in the United States. in 2022, and more than 49,830 patients will die from the disease -- the highest mortality rate of all major cancers. For advanced disease, chemotherapy (sometimes along with a targeted drug therapy) may lengthen survival.1

Key Points: 
  • In three of these models, significant changes in tumor growth were observed in those that received QN-302, together with good tolerance and bioavailability at therapeutic doses.
  • This news release contains forward-looking statements by Qualigen that involve risks and uncertainties and reflect the Company's judgment as of the date of this release.
  • The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law.
  • This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Qualigen Therapeutics Announces Three Published Abstracts at American Association of Cancer Research Conference

Retrieved on: 
Tuesday, March 22, 2022
Company, Private Securities Litigation Reform Act, PDX, Therapy, Cancer, Cell, Survivor, Fast Track, Form 10-K, Acute myeloid leukemia, DNA, Patent, AML, Risk, Clinical trial, Oncogene, Adult, AACR, American Association, Conference, Neoplasm, G4S, Medicine, U.S. Securities and Exchange Commission, Treatment of lung cancer, 2021 Essex County Council election, PDAC, PC3, Protein, Orphan drug, Prostate cancer, Nasdaq, RAS, GLOBE, News, Animal, Water, FDA, Pancreatic cancer, American Association for Cancer Research, Patient, Security (finance), Pharmaceutical industry, Medical imaging

CARLSBAD, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today provides data from published abstracts from the American Association of Cancer Research (AACR) demonstrating positive in vivo data on the Company’s lead compound QN-302 (previously known and referenced in the abstracts as SOP1812).

Key Points: 
  • These data represent an important step forward in our lead development program, QN-302, particularly with regard to pancreatic cancer and prostate cancer, commented Michael Poirier, Qualigens CEO.
  • The presentation of these data at AACR shows promising information regarding the key properties of this therapeutic target.
  • The potent quadruplex-binding compound SOP1812 shows anti-tumor activity in patient-derived in vivo models of pancreatic cancer (lead author Dr. Stephen Neidle, to be posted April 13).
  • These abstract reports that QN-302 showed significant anti-tumor activity in three patient-derived xenograft (PDX) models for pancreatic ductal adenocarcinoma (PDAC).

Nexon Releases Earnings For Third Quarter 2021

Retrieved on: 
Tuesday, November 9, 2021
Entertainment, Technology, Online, Mobile, Wireless, Mobile Entertainment, Electronic Games, Net, PlayStation, EA, Crazyracing Kartrider, Tokyo Stock Exchange, Movement, CEO, EST, Technology, Chuseok, Machine learning, Income, Growth, Dungeon, Kingdom, National, FIFA, Foreign exchange market, NEXON, Translation, MapleStory, Participation, Sale, JST, National day, NAT, PC3, Tencent, Xbox, Q&A, Nikkei, Yuan (currency), PC, Name, Card security code, Video game, Pharmaceutical industry, Weapon, Security (finance)

NEXON Co., Ltd. (Nexon) (3659.TO), a global leader in Virtual Worlds, today announced the financial results for its third quarter ended September 30, 2021.

Key Points: 
  • NEXON Co., Ltd. (Nexon) (3659.TO), a global leader in Virtual Worlds, today announced the financial results for its third quarter ended September 30, 2021.
  • In Korea, MapleStory showed a second quarter of sequential improvement in Net Promoter Score a key indicator of player satisfaction.
  • On November 1, Nexon announced plans to launch Mobile Dungeon&Fighter in Korea during the first quarter of 2022.
  • Founded in 1994, NEXON Co., Ltd. (Nexon) (3659.TO) is a company engaged in the production, development and operation of online games and Virtual Worlds.